Laden... Bitte warten

Company profile

Sequana Medical N.V. is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump is a fully-implanted, wireless device that automatically pumps fluid from the abdomen into the bladder, where it is removed naturally through urination. The alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and has been granted breakthrough device designation by the US FDA with a North American pivotal study underway. DSR is a novel approach to manage sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity. The alfapump DSR® combines DSR therapy with the proven alfapump platform and is in clinical development as potential treatment for decompensated heart failure patients.

Source: Cofisem - Last Update: 16 Oct 2024
Key Executives
Chief Executive Officer Ian Crosbie
Chief Financial Officer Kirsten Van Bockstaele
Chief Commercial Officer Martijn Blom
Source: Cofisem - Last Update: 16 Oct 2024
Key figures
Millenium 2023 2022 2021 2020 2019
Net sales 712 923 371 963 971
Income from ordinary activities 712 923 371 963 971
Operating income -28.862 -28.094 -22.614 -17.771 -13.964
Cost of financial indebtedness net 1.989 880 466 1.066 771
Equity-accounted companies contribution to income
Net profit from discontinued activities
Net income -32.564 -30.763 -23.615 -19.106 -14.977
Net income (Group share) -32.564 -30.763 -23.615 -19.106 -14.977
Fiscal year end 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards IFRS IFRS IFRS IFRS IFRS
Source: Cofisem - Last Update: 16 Oct 2024
Shareholder information
Other shareholders 39,80 %
EQT Life Sciences Group B.V. 13,10 %
FPIM -SFPI NV 5,30 %
Grac Société Simple 5,20 %
MCMI SPV Holdco Inc. 7,10 %
Newton Biocapital 3,10 %
Pi Equity 16,90 %
Rosetta Capital Ltd 5,60 %
Sensinnovat BVBA 3,90 %
Source: Cofisem - Last Update: 16 Oct 2024

Adresse

Sequana Medical N.V.

Kortrijksesteenweg 1112
box 102
BE-9051 Sint-Denijs-Westrem
Belgium
Telefonnummer: +32 9 298 2828
Source: Cofisem - Last Update: 16 Oct 2024

Kontakt

Lies Vanneste
Telefonnummer: +32 498 053579
Source: Sequana Medical N.V. - Last Update: 16 Oct 2024